Quick summary
Cortexin is a bovine cerebral cortex polypeptide preparation registered in Russia since 1999 for stroke, TBI, and cognitive impairment. Its low-molecular-weight fractions cross the blood-brain barrier with neuroprotective effects comparable to Cerebrolysin.
Overview
Cortexin is a polypeptide preparation extracted from the cerebral cortex of cattle, developed in part by the Khavinson research group and registered as a pharmaceutical drug in Russia since 1999. It is approved in Russia and several Eastern European countries for treatment of stroke, traumatic brain injury, and cognitive impairment. It contains low-molecular-weight water-soluble polypeptide fractions (1,000–10,000 Da) that cross the blood-brain barrier.
Mechanism of action
Cortexin contains a complex mixture of polypeptides, amino acids, and trace elements from bovine cerebral cortex that cross the blood-brain barrier and directly interact with neuronal cells. Its neuroprotective mechanism involves regulating the balance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmitters, modulating dopamine and serotonin signaling, and reducing paroxysmal seizure activity. At the molecular level, Cortexin peptides interact with neuron-specific proteins including β5-tubulin, creatine kinase B, and protein 14-3-3 α/β, engaging pathways governing signal transduction, energy metabolism, proteolytic protein modification, cell structure, and neuroinflammation. These multi-target actions promote neuroplasticity and neuroprotection after ischemic or traumatic injury. The preparation also reduces oxidative stress in neuronal tissue and supports neurotrophic factor activity.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| neuroprotection / cognitive research | intramuscular | 10–10 mg | daily for 10 days | Standard Russian clinical protocol: 10 mg IM daily for 10 days. Reconstitute in 1–2 mL sterile saline. Courses repeated 2–3 times per year. Pediatric dosing uses 5 mg. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Cortexin has been studied in Russian and international clinical trials for ischemic stroke, TBI, and cognitive impairment. Comparative studies show neuroprotective effects comparable to Cerebrolysin and Actovegin in acute brain ischemia models. A 2021 PMC-indexed study demonstrated significantly reduced cortical neuron loss in rat cerebral ischemia models. Clinical use in Russia spans over 25 years with documented efficacy in stroke recovery programs. A Cochrane-level systematic review does not exist for Cortexin specifically; evidence quality by Western standards remains moderate. It is approved by the Russian Ministry of Health for neurological conditions.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Cortexin for synergistic effects.
Legal status
Registered pharmaceutical drug approved in Russia (1999) and several Eastern European countries. Not FDA-approved. Available in Western markets only as a research substance. Not approved for therapeutic human use in the US or EU. Comparable to Cerebrolysin in regulatory status.
Sourcing & access
Research compound
Cortexin is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Cortexin is a polypeptide preparation extracted from bovine cerebral cortex, registered in Russia since 1999 for treatment of stroke, traumatic brain injury, and cognitive impairment. It contains water-soluble polypeptide fractions (1,000-10,000 Da) that cross the blood-brain barrier.
Cortexin regulates the balance between excitatory glutamatergic and inhibitory GABAergic neurotransmission, modulates dopamine and serotonin signaling, and interacts with neuron-specific proteins including beta5-tubulin and creatine kinase B. These multi-target actions promote neuroplasticity, reduce oxidative stress, and support neuroprotection after ischemic or traumatic injury.
Side effects are generally mild and rare, including injection site pain, transient dizziness, headache, and rare allergic reactions. It has over 25 years of clinical use in Russia. Evidence quality by Western standards remains moderate, with no Cochrane-level systematic review available.
The standard Russian clinical protocol is 10 mg intramuscularly daily for 10 days, reconstituted in 1-2 mL sterile saline. Courses are repeated 2-3 times per year. Pediatric dosing uses 5 mg.
Research references
- Neuroprotective Action of Cortexin, Cerebrolysin and Actovegin in Acute or Chronic Brain Ischemia in RatsPubMed
- Molecular Mechanisms of Brain Peptide-Containing Drugs: CortexinPubMed
- Peptide Drug Cortexin Inhibits Brain Caspase-8PubMed
- Comparative Analysis of Efficacy of Certain Neuroprotectors in Ischemic StrokePubMed
- Cortexin Ameliorates High Glucose-Induced Neuropathy in Cultured Rat Sensory NeuronsPubMed